Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.52 |
| ▸ | SRC | P12931 | 8/20 | 0.52 |
| ▸ | KDR | P35968 | 3/20 | 0.52 |
| ▸ | FLT1 | P17948 | 2/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | SYK | P43405 | 1/20 | 0.52 |
| ▸ | MAP2K1 | Q02750 | 4/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15265722 | 0.90 | EGFR (0.61) | EGFRERBB2SRCKDRFLT1 | |
| SCHEMBL1893862 | 0.90 | EGFR (0.61) | EGFRERBB2SRCKDRFLT1 | |
| SCHEMBL6182401 | 0.87 | SRC (0.54) | EGFRERBB2SRCKDRFLT1 | |
| SCHEMBL4786042 | 0.85 | SRC (0.63) | EGFRERBB2SRCKDRFLT1 | |
| SCHEMBL6185004 | 0.82 | EGFR (0.46) | EGFRERBB2SRCKDRMAP2K1 | |
| SCHEMBL16543980 | 0.82 | EGFR (0.46) | EGFRERBB2SRCKDRMAP2K1 | |
| SCHEMBL22589792 | 0.80 | SRC (0.56) | EGFRERBB2SRCKDRFLT1 | |
| SCHEMBL29363297 | 0.80 | SRC (0.56) | EGFRERBB2SRCKDRFLT1 | |
| SCHEMBL4742038 | 0.78 | EGFR (0.62) | EGFRERBB2SRCKDRFLT1 | |
| SCHEMBL4742854 | 0.78 | EGFR (0.62) | EGFRERBB2SRCKDRFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100354263-C | Process for the preparation of 7-substituted-3-quinoline and 3-quinol-4-one carbonitriles | WYETH CORP (US) | 2007-12-12 | — | — | CN | disclosed |
| CN-1665787-A | Process for preparing 7-substituted-3-quinolines and 3-quinol-4-one carbonitriles | WYETH CORP (US) | 2005-09-07 | — | — | CN | disclosed |
| EP-1499594-B1 | PROCESS FOR THE PREPARATION OF 7-SUBSTITUTED-3-QUINOLINE AND 3-QUINOL-4-ONE CARBONITRILES | WYETH CORP (US) | 2005-08-17 | — | — | EP | disclosed |
| EP-1499594-A1 | PROCESS FOR THE PREPARATION OF 7-SUBSTITUTED-3-QUINOLINE AND 3-QUINOL-4-ONE CARBONITRILES | Wyeth Holdings Corporation (US) | 2005-01-26 | — | — | EP | disclosed |
| US-6780996-B2 | KINASE INHIBITORS; ANTICANCER AGENTS | WYETH HOLDINGS CORPORATION | 2004-08-24 | — | — | US | disclosed |
| US-20030212276-A1 | Process for the preparation of 7-substituted-3 quinolinecarbonitriles | WYETH HOLDINGS CORPORATION | 2003-11-13 | — | — | US | disclosed |
| WO-2003093241-A1 | PROCESS FOR THE PREPARATION OF 7-SUBSTITUTED-3-QUINOLINE AND 3-QUINOL-4-ONE CARBONITRILES | WYETH HOLDINGS CORPORATION (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212276-A1 | Process for the preparation of 7-substituted-3 quinolinecarbonitriles | MAP4K2, MAP3K7, MAP4K1 | EGFR 1394/4885ERBB2 395/4885SRC 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.